Business News • PR NewsWire • Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to Prevent the Onset of Rheumatoid Arthritis and Potency in Treating and Reversing Bone and Cartilage Damage In Preclinical Models |
Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to Prevent the Onset of Rheumatoid Arthritis and Potency in Treating and Reversing Bone and Cartilage Damage In Preclinical Models |
|
|
|